<DOC>
	<DOCNO>NCT00297895</DOCNO>
	<brief_summary>Subjects must diagnose melanoma . All subject receive sentinel lymphadenectomy . If subject sentinel node positive meet study requirement , subject randomize receive either ( 1 ) completion lymphadenectomy ( 2 ) observation nodal ultrasound . Subjects follow 10 year .</brief_summary>
	<brief_title>Multicenter Selective Lymphadenectomy Trial II ( MSLT-II )</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Ability provide inform consent . 2 . Between 18 75 year age . 3 . Have primary melanoma cutaneous ( include head , neck , trunk , extremity , scalp , palm , sole , subungual skin tissue ) . 4 . Have clear margin follow WLE . 5 . ECOG performance status 01 . 6 . Life expectancy least 10 year time diagnosis , consider melanoma question , determine PI . 7 . Willing return MSLTII center follow examination procedure outline protocol . 8 . Randomization and/or CLND ( appropriate randomization arm ) must complete 120 day follow diagnostic biopsy primary melanoma . 9 . Have melanomarelated tumorpositive SN , determine either follow method : 1 . Diagnosis tumorpositive SN MSLTII center institutional pathologist either H &amp; E IHC ( use S100 , Mart1 , HMB45 ) . 2 . Diagnosis tumorpositive SN RTPCR analysis perform JWCI , provide primary melanoma fit one follow category : Breslow thickness 1.20 mm great Clark Level III Clark Level IV V , regardless Breslow thickness Ulceration , regardless Breslow thickness Clark level 1 . History previous concurrent ( i.e. , second primary ) invasive melanoma . 2 . Primary melanoma eye , ear , mucous membrane internal viscera . ( Primary skin external ear acceptable . ) 3 . Physical , clinical , radiographic pathologic evidence satellite , intransit , regional , distant metastatic disease . 4 . Any additional solid tumor hematologic malignancy past 5 year except T1 skin lesion squamous cell carcinoma , basal cell carcinoma , uterine cervical cancer . 5 . Skin graft , tissue transfer flap potential alter lymphatic drainage pattern primary melanoma LN basin . 6 . Allergy vital blue dye radiocolloid . 7 . Inability localize 12 SN drainage basins via LM ( e.g. , basins find , 2 basin find , proximity primary melanoma regional draining basin , etc . ) 8 . CLNDs SLs ( evaluation current melanoma ) may alter lymphatic drainage pattern primary cutaneous melanoma potential LN basin . 9 . Organic brain syndrome significant impairment basal cognitive function psychiatric disorder might preclude participation full protocol , exacerbate therapy ( e.g. , severe depression ) . 10 . Melanomarelated operative procedure correspond criterion describe protocol . 11 . Primary secondary immune deficiency know significant autoimmune disease . 12 . History organ transplantation . 13 . Oral parenteral immunosuppressive agent ( topical inhale steroid ) time study participation within 6 month prior enrollment . 14 . Pregnant lactating woman . 15 . Participation concurrent therapy protocol alternative local nodal basin therapy might confound analysis trial permit . For example , radiation nonresected node basin acceptable might influence outgrowth residual melanoma nodal basin . However , systemic adjuvant therapy clinical trial adjuvant protocols find positive node LM/SL delay nodal recurrence ultrasound observation arm acceptable accord standard care multicenter site . Patients positive sentinel node thick primary melanoma consider multicenter site 's investigator highrisk may receive systemic adjuvant therapy accord standard practice particular site . 16 . SLND pathology show , microscopic examination , melanoma extend lymph node capsule adjacent soft tissue .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>sentinel lymph node dissection</keyword>
	<keyword>complete lymph node dissection</keyword>
	<keyword>surgical</keyword>
</DOC>